Cargando…
The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma
We focused on the therapeutic effect of pembrolizumab for metastatic urothelial carcinoma (mUC) and evaluated predictive factors for improving clinical outcomes. We conducted a retrospective multicenter cohort study of patients with mUC who received pembrolizumab. The endpoint was to evaluate the as...
Autores principales: | Tomioka-Inagawa, Risa, Nakane, Keita, Enomoto, Torai, Tomioka, Masayuki, Taniguchi, Tomoki, Ishida, Takashi, Ozawa, Kaori, Takagi, Kimiaki, Ito, Hiroki, Takeuchi, Shinichi, Kawase, Makoto, Kawase, Kota, Kato, Daiki, Takai, Manabu, Iinuma, Koji, Yokoi, Shigeaki, Nakano, Masahiro, Koie, Takuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313086/ https://www.ncbi.nlm.nih.gov/pubmed/35884914 http://dx.doi.org/10.3390/biomedicines10071609 |
Ejemplares similares
-
Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study
por: Yamada, Toyohiro, et al.
Publicado: (2022) -
Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2022) -
Clinical Lymph Node Involvement as a Predictor for Cancer-Specific Survival in Patients with Penile Squamous Cell Cancer
por: Kawase, Makoto, et al.
Publicado: (2022) -
Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2022) -
Robot-Assisted Radical Prostatectomy for Potential Cancer Control in Patients with Metastatic Prostate Cancer
por: Takagi, Kimiaki, et al.
Publicado: (2022)